Everi - EVRI Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Everi in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EVRI shares.
View EVRI analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month target prices for Everi's stock. Their EVRI share price forecasts range from $24.00 to $35.00. On average, they expect the company's share price to reach $28.75 in the next twelve months. This suggests a possible upside of 77.3% from the stock's current price.
View analysts price targets for EVRI or view top-rated stocks among Wall Street analysts.

Everi's stock was trading at $21.35 at the start of the year. Since then, EVRI stock has decreased by 24.0% and is now trading at $16.22.
View the best growth stocks for 2022 here.

Everi saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 2,180,000 shares, a decline of 8.4% from the August 15th total of 2,380,000 shares. Based on an average daily trading volume, of 653,000 shares, the days-to-cover ratio is currently 3.3 days. Currently, 2.5% of the company's stock are short sold.
View Everi's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our EVRI earnings forecast.

Everi Holdings Inc. (NYSE:EVRI) posted its quarterly earnings results on Wednesday, August, 3rd. The credit services provider reported $0.33 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.33. The credit services provider earned $197.22 million during the quarter, compared to the consensus estimate of $182.21 million. Everi had a trailing twelve-month return on equity of 73.32% and a net margin of 21.84%.

75 employees have rated Everi Chief Executive Officer Michael D. Rumbolz on Glassdoor.com. Michael D. Rumbolz has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Everi investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), OrganiGram (OGI), New Residential Investment (NRZ), General Electric (GE), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), Sorrento Therapeutics (SRNE) and Nokia Oyj (NOK).

Everi trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVRI."

Shares of EVRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVRI stock can currently be purchased for approximately $16.22.

Everi (NYSE:EVRI) has a market capitalization of $1.46 billion and generates $660.39 million in revenue each year. The credit services provider earns $152.93 million in net income (profit) each year or $1.59 on an earnings per share basis.

The company employs 1,550 workers across the globe.

Everi's mailing address is 7250 S. Tenaya Way Suite 100, Las Vegas NV, 89113. The official website for the company is www.everi.com. The credit services provider can be reached via phone at (800) 833-7110, via email at evri@jcir.com, or via fax at 866-672-4371.